L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.
Immunosuppressive disease is independently associated with significantly shorter survival among patients with CSCC receiving ICI therapy.
Investigators sought to determine whether adding gedatolisib to fulvestrant, with or without palbociclib, improved clinical outcomes in patients with HR-positive/HER2-negative/PIK3CA wild-type ...
Investigators delivered updated results from the phase 3 PHILA trial evaluating the pyrotinib or placebo plus trastuzumab and docetaxel in patients with untreated HER2+metastatic breast cancer.
Across treatment classes, CH associated with increased therapy-related cytopenias, particularly neutropenia, and DNMT3A/TET2 ...
Piqray plus Faslodex significantly improved PFS in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer after CDK4/6 inhibitor treatment. The EPIK-B5 study reported a median ...
Adding lenvatinib to pembrolizumab improved PFS (6.2 vs 2.8 months; HR 0.64) and ORR (46.1% vs 25.4%) versus pembrolizumab ...
A randomized phase 2 maintenance strategy with cabozantinib 60 mg daily for up to 2 years failed to improve 4-month PFS ...
LONDON--(BUSINESS WIRE)--Today, Prepaid Financial Services has finalised its acquisition by EML and has become part of a listed entity, EML Payments. PFS/EML is now one of the largest prepaid FinTech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results